Solenn Brosseau

8.3k total citations
53 papers, 711 citations indexed

About

Solenn Brosseau is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Solenn Brosseau has authored 53 papers receiving a total of 711 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Solenn Brosseau's work include Lung Cancer Treatments and Mutations (25 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Occupational and environmental lung diseases (11 papers). Solenn Brosseau is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Occupational and environmental lung diseases (11 papers). Solenn Brosseau collaborates with scholars based in France, United States and Australia. Solenn Brosseau's co-authors include Gérard Zalcman, V. Gounant, Sandra Assoun, Claire Danel, Antoine Khalil, Nathalie Théou–Anton, Johan Pluvy, Aurélie Cazes, Baptiste Abbar and Céline Namour and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Solenn Brosseau

49 papers receiving 704 citations

Peers

Countries citing papers authored by Solenn Brosseau

Since Specialization

Citations

This map shows the geographic impact of Solenn Brosseau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Solenn Brosseau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Solenn Brosseau more than expected).

Fields of papers citing papers by Solenn Brosseau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Solenn Brosseau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Solenn Brosseau. The network helps show where Solenn Brosseau may publish in the future.

Co-authorship network of co-authors of Solenn Brosseau

This figure shows the co-authorship network connecting the top 25 collaborators of Solenn Brosseau. A scholar is included among the top collaborators of Solenn Brosseau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Solenn Brosseau. Solenn Brosseau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial 2025 ·Translational Oncology ·Guénaëlle Levallet, Christian Créveuil, (unknown), Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Sylvie Lantuéjoul, Julien Mazières, Laurent Greillier, Clarisse Audigier-Valette, Emmanuel Bergot, Denis Moro‐Sibilot, Olivier Molinier, H. Léna, Isabelle Monnet, Franck Morin, V. Gounant, Gérard Zalcman	1
2	Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP 2022 ·Targeted Oncology ·Fatéméh Dubois, Céline Bazille, Jérôme Levallet, (unknown), Solenn Brosseau, J. Madelaine, Emmanuel Bergot, Gérard Zalcman, Guénaëlle Levallet	8
3	EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy 2021 ·Cancers ·(unknown), (unknown), Karen Leroy, I. Monnet, Solenn Brosseau, Nathalie Théou–Anton, Marie-Ange Massiani, S. Friard, Boris Duchemann, Elizabeth Fabre, Etienne Giroux‐Leprieur, Jacques Cadranel, Marie Wislez	14
4	Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway 2021 ·Lung Cancer ·(unknown), Johan Pluvy, Nathalie Théou–Anton, (unknown), Nicolas Poté, Solenn Brosseau, V. Gounant, Gérard Zalcman	6
5	Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête 2021 ·Revue des Maladies Respiratoires Actualités ·V. Gounant, Solenn Brosseau, (unknown), Johan Pluvy, (unknown), (unknown), (unknown), Céline Namour, Gérard Zalcman	0
6	Specific Genomic Alterations in High-Grade Pulmonary Neuroendocrine Tumours with Carcinoid Morphology 2020 ·Neuroendocrinology ·Jérôme Cros, Nathalie Théou–Anton, V. Gounant, Rémy Nicolle, Cécile Réyès, (unknown), S. Hescot, Vincent de Montpréville, Serge Guyétant, Jean‐Yves Scoazec, Alice Guyard, Louis de Mestier, Solenn Brosseau, Pierre Mordant, Yves Castier, David Gentien, Philippe Ruszniewski, Gérard Zalcman, Anne Couvelard, Aurélie Cazes	32
7	1389P IFCT-1602 CHIVA2 phase II trial: Nivolumab in previously treated HIV-patients with advanced non-small cell lung cancer (NSCLC) 2020 ·Annals of Oncology ·A. Lavolé, Julien Mazières, S. Schneider, Solenn Brosseau, (unknown), Laurent Greillier, Amélie Guihot, Baptiste Abbar, Marine Baron, Alain Makinson, Alexandra Langlais, Franck Morin, (unknown), J. Cadranel	4
8	Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors 2020 ·BMC Cancer ·(unknown), Johan Pluvy, (unknown), (unknown), Solenn Brosseau, (unknown), (unknown), Nathalie Théou–Anton, Alice Guyard, (unknown), Antoine Khalil, Gérard Zalcman, V. Gounant	8
9	Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer 2019 ·Lung Cancer ·Sandra Assoun, Nathalie Théou–Anton, (unknown), Aurélie Cazes, Claire Danel, Baptiste Abbar, Johan Pluvy, V. Gounant, Antoine Khalil, Céline Namour, Solenn Brosseau, Gérard Zalcman	117
10	Safe and effective use of nivolumab for treating lung adenocarcinoma associated with sporadic lymphangioleiomyomatosis: a rare case report 2019 ·BMC Pulmonary Medicine ·Johan Pluvy, Solenn Brosseau, (unknown), Claire Danel, (unknown), Antoine Khalil, Bruno Crestani, Gérard Zalcman, V. Gounant	5
11	MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial 2019 ·British Journal of Cancer ·(unknown), Solenn Brosseau, (unknown), Christian Créveuil, Claire Danel, Emmanuel Bergot, Arnaud Scherpereel, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, R. Corre, I. Monnet, V. Gounant, Alexandra Langlais, Franck Morin, Guénaëlle Levallet, Gérard Zalcman	17
12	Lazarus Syndrome With Crizotinib in a Non–Small Cell Lung Cancer Patient With ROS1 Rearrangement and Disseminated Intravascular Coagulation 2017 ·Clinical Lung Cancer ·Solenn Brosseau, V. Gounant, Charles Naltet, Nathalie Théou–Anton, Aurélie Cazes, Roland Smonig, Mathilde Neuville, Antoine Khalil, Nidaa Mikaïl, Véronique Meignin, Anne Bergeron, Gérard Zalcman	4
13	Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO) 2017 ·Annals of Oncology ·Roberto Ferrara, Caroline Caramella, Matthieu Texier, Clarisse Audigier-Valette, Laurent Tessonnier, Laura Mezquita, J. Lahmar, Julien Mazières, Gérard Zalcman, Solenn Brosseau, Virginie Westeel, Sylvestre Le Moulec, Laura Leroy, Boris Duchemann, Rémi Veillon, David Planchard, (unknown), Serge Koscielny, J.C. Soria, Benjamin Besse	19
14	The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients 2017 ·Annals of Oncology ·Laura Mezquita, Édouard Auclin, Mélinda Charrier, Roberto Ferrara, J. Remon Masip, David Planchard, Santiago Ponce Aix, Luis Paz‐Ares, J. Lahmar, Laura Leroy, Clarisse Audigier-Valette, (unknown), Pilar Garrido, Solenn Brosseau, Julien Mazières, Caroline Caramella, Julien Adam, Nathalie Chaput, Jean‐Charles Soria, Benjamin Besse	5
15	EGFR tyrosine kinase inhibitorsversuschemotherapy inEGFRwild-type pre-treated advanced nonsmall cell lung cancer in daily practice 2017 ·European Respiratory Journal ·Pascale Tomasini, Solenn Brosseau, Julien Mazières, Jean‐Philippe Merlio, Michèle Beau‐Faller, Jean Mosser, Marie Wislez, L’Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, D. Debieuvre, Fabienne Escande, Virginie Westeel, Clarisse Audigier-Valette, Pascale Missy, Alexandra Langlais, (unknown), Denis Moro‐Sibilot, Gérard Zalcman, Fabrice Barlési	21
16	Traitements péri-opératoires des carcinomes bronchiques non à petites cellules 2017 ·Revue des Maladies Respiratoires ·Solenn Brosseau, Charles Naltet, (unknown), V. Gounant, Pierre Mordant, B. Milleron, Yves Castier, Gérard Zalcman	1
17	Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma 2016 ·Lung Cancer ·V. Gounant, Solenn Brosseau, Charles Naltet, (unknown), Martine Antoine, Claire Danel, Antoine Khalil, Jacques Cadranel, Gérard Zalcman	31
18	Pulmonary complications of type 1 neurofibromatosis 2016 ·Revue des Maladies Respiratoires ·(unknown), Barbara Girerd, Andrei Seferian, Katrina Campbell, Solenn Brosseau, Emmanuel Bergot, Marc Humbert, Gérard Zalcman, David Montani	14
19	Inhibiteurs de ALK de 2e génération dans le cancer bronchique non à petites cellules : revue de la littérature 2015 ·Bulletin du Cancer ·Marie Viala, Solenn Brosseau, David Planchard, Benjamin Besse, Jean‐Charles Soria	6
20	Mésothéliomes malins pleuraux : le point en 2013 2013 ·Bulletin du Cancer ·(unknown), Solenn Brosseau, (unknown), Emmanuel Bergot, Emmanuèle Lechapt, Guénaëlle Levallet, Gérard Zalcman	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact